Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is a promising company with strong financials and potential for growth, supported by its successful strategy and increasing demand for its MRD product. However, possible challenges with EMR integrations and competition may impact future performance. It has a favorable ESG performance and a solid cash position, making it a strong investment opportunity for those with a positive outlook on the company.

Bears say

Adaptive Biotechnologies is facing several key risks, including challenges in gaining customer adoption and launching new products, potential competition in the market, possible hurdles in obtaining reimbursement and navigating clinical guidelines, and the company's high valuation. While the company's immune-driven medicine platform and FDA-approved recurrence monitoring test show promise, it remains to be seen whether they will be able to establish a strong foothold in the market and generate significant revenue. Furthermore, the process of gathering data from numerous sources may present operational risks.

Adaptive Biotechnologies (ADPT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 7 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.